No Data
No Data
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Austar Lifesciences to Swing to Profit in H1
Austar announced profit forecast, with an expected mid-term profit of approximately 3 to 6 million yuan for shareholders.
Austar (06118) announced that it is expected to obtain a profit of approximately RMB 3 million to RMB 6 million attributable to owners of the company for the six months ending June 30, 2024, while the loss attributable to owners of the company for the six months ending June 30, 2023 is approximately RMB 40 million. The expected turnaround from loss to profit is mainly due to: (1) no losses from the indirect non-wholly owned subsidiaries, H+E Pharma GmbH and S-Tec GmbH, of the company at that time, with a loss of approximately RMB 63.9 million for the six months ending June 30, 2023 (-).
Austar Lifesciences Anticipates Profit Turnaround
Austar Life Sciences (06118) announced a profit warning, with an expected interim net profit attributable to shareholders ranging from approximately 3 million to 6 million yuan.
Austar Life Sciences (06118) announced that it is expected to acquire the six-month company ending on June 30, 2024...
Express News | Austar Lifesciences - Expected Result Due to Saving of Operating Expenses of RMB10 Mln, Among Others
No Data